schliessen

Filtern

 

Bibliotheken

The effect of tenofovir disoproxil fumarate on whole-body insulin sensitivity, lipids and adipokines in healthy volunteers.

BACKGROUNDCertain antiretrovirals are known to affect lipid and glucose homeostasis. The aim of this study was to assess the effect on insulin sensitivity (determined by peripheral glucose uptake using a hyperinsulinaemic euglycaemic clamp) of tenofovir disoproxil fumarate (TDF) administration compa... Full description

Journal Title: Antiviral therapy 2010, Vol.15(2), pp.227-233
Main Author: Randell, Paul A
Other Authors: Jackson, Akil G , Zhong, Lijie , Yale, Kitty , Moyle, Graeme J
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: E-ISSN: 2040-2058 ; DOI: 2040-2058 ; DOI: 10.3851/IMP1518
Link: http://search.proquest.com/docview/733880007/?pq-origsite=primo
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: proquest733880007
title: The effect of tenofovir disoproxil fumarate on whole-body insulin sensitivity, lipids and adipokines in healthy volunteers.
format: Article
creator:
  • Randell, Paul A
  • Jackson, Akil G
  • Zhong, Lijie
  • Yale, Kitty
  • Moyle, Graeme J
subjects:
  • Adenine–Administration & Dosage
  • Adipokines–Analogs & Derivatives
  • Adult–Pharmacology
  • Anti-HIV Agents–Metabolism
  • Cholesterol–Administration & Dosage
  • Cholesterol, LDL–Pharmacology
  • Cross-Over Studies–Metabolism
  • Drug Administration Schedule–Drug Effects
  • Glucose Clamp Technique–Metabolism
  • HIV Seronegativity–Drug Effects
  • Humans–Metabolism
  • Insulin–Drug Effects
  • Insulin Resistance–Administration & Dosage
  • Lipid Metabolism–Pharmacology
  • Male–Administration & Dosage
  • Organophosphonates–Pharmacology
  • Reverse Transcriptase Inhibitors–Pharmacology
  • Tenofovir–Pharmacology
  • Treatment Outcome–Pharmacology
  • Young Adult–Pharmacology
  • Adipokines
  • Anti-HIV Agents
  • Cholesterol, LDL
  • Insulin
  • Organophosphonates
  • Reverse Transcriptase Inhibitors
  • Cholesterol
  • Tenofovir
  • Adenine
ispartof: Antiviral therapy, 2010, Vol.15(2), pp.227-233
description: BACKGROUNDCertain antiretrovirals are known to affect lipid and glucose homeostasis. The aim of this study was to assess the effect on insulin sensitivity (determined by peripheral glucose uptake using a hyperinsulinaemic euglycaemic clamp) of tenofovir disoproxil fumarate (TDF) administration compared with placebo for 2 weeks in HIV-1-seronegative healthy male volunteers. Changes in lipids, adiponectin, leptin, plasminogen activator inhibitor 1 (PAI-1) and the adhesion molecules E-selectin and P-selectin were also assessed. METHODSThis was a single-centre, randomized, double-blinded, placebo-controlled study that used a two-sequence, two-period cross-over design. A total of 19 HIV-negative males were recruited to the study and randomized 1:1 to receive either 2 weeks of TDF (300 mg once daily) followed by 2 weeks of placebo or placebo initially followed by tenofovir. Clamps were performed at baseline, after 2 weeks and after 4 weeks. RESULTSAll three clamps were completed by 16 participants. During the euglycaemic clamp, there were no significant changes in insulin sensitivity after 2 weeks of TDF administration compared with placebo or baseline. There was a significant reduction in the mean total cholesterol (9.4%) and low-density lipoprotein (LDL; 8.1%) cholesterol following 2 weeks of TDF compared with placebo. Levels of adiponectin, leptin, PAI-1, P-selectin and E-selectin were not significantly altered. CONCLUSIONSTDF use for 2 weeks does not affect insulin sensitivity, as assessed by the hyperinsulinaemic euglycaemic clamp in HIV-negative male volunteers. TDF use resulted in modest, but statistically significant, reductions in total and LDL cholesterol.
language: eng
source:
identifier: E-ISSN: 2040-2058 ; DOI: 2040-2058 ; DOI: 10.3851/IMP1518
fulltext: fulltext
issn:
  • 20402058
  • 2040-2058
url: Link


@attributes
ID1763248725
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid733880007
sourceidproquest
recordidTN_proquest733880007
sourcesystemOther
pqid733880007
display
typearticle
titleThe effect of tenofovir disoproxil fumarate on whole-body insulin sensitivity, lipids and adipokines in healthy volunteers.
creatorRandell, Paul A ; Jackson, Akil G ; Zhong, Lijie ; Yale, Kitty ; Moyle, Graeme J
contributorRandell, Paul A (correspondence author) ; Randell, Paul A (record owner)
ispartofAntiviral therapy, 2010, Vol.15(2), pp.227-233
identifier
subjectAdenine–Administration & Dosage ; Adipokines–Analogs & Derivatives ; Adult–Pharmacology ; Anti-HIV Agents–Metabolism ; Cholesterol–Administration & Dosage ; Cholesterol, LDL–Pharmacology ; Cross-Over Studies–Metabolism ; Drug Administration Schedule–Drug Effects ; Glucose Clamp Technique–Metabolism ; HIV Seronegativity–Drug Effects ; Humans–Metabolism ; Insulin–Drug Effects ; Insulin Resistance–Administration & Dosage ; Lipid Metabolism–Pharmacology ; Male–Administration & Dosage ; Organophosphonates–Pharmacology ; Reverse Transcriptase Inhibitors–Pharmacology ; Tenofovir–Pharmacology ; Treatment Outcome–Pharmacology ; Young Adult–Pharmacology ; Adipokines ; Anti-HIV Agents ; Cholesterol, LDL ; Insulin ; Organophosphonates ; Reverse Transcriptase Inhibitors ; Cholesterol ; Tenofovir ; Adenine
descriptionBACKGROUNDCertain antiretrovirals are known to affect lipid and glucose homeostasis. The aim of this study was to assess the effect on insulin sensitivity (determined by peripheral glucose uptake using a hyperinsulinaemic euglycaemic clamp) of tenofovir disoproxil fumarate (TDF) administration compared with placebo for 2 weeks in HIV-1-seronegative healthy male volunteers. Changes in lipids, adiponectin, leptin, plasminogen activator inhibitor 1 (PAI-1) and the adhesion molecules E-selectin and P-selectin were also assessed. METHODSThis was a single-centre, randomized, double-blinded, placebo-controlled study that used a two-sequence, two-period cross-over design. A total of 19 HIV-negative males were recruited to the study and randomized 1:1 to receive either 2 weeks of TDF (300 mg once daily) followed by 2 weeks of placebo or placebo initially followed by tenofovir. Clamps were performed at baseline, after 2 weeks and after 4 weeks. RESULTSAll three clamps were completed by 16 participants. During the euglycaemic clamp, there were no significant changes in insulin sensitivity after 2 weeks of TDF administration compared with placebo or baseline. There was a significant reduction in the mean total cholesterol (9.4%) and low-density lipoprotein (LDL; 8.1%) cholesterol following 2 weeks of TDF compared with placebo. Levels of adiponectin, leptin, PAI-1, P-selectin and E-selectin were not significantly altered. CONCLUSIONSTDF use for 2 weeks does not affect insulin sensitivity, as assessed by the hyperinsulinaemic euglycaemic clamp in HIV-negative male volunteers. TDF use resulted in modest, but statistically significant, reductions in total and LDL cholesterol.
languageeng
source
version4
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
backlink$$Uhttp://search.proquest.com/docview/733880007/?pq-origsite=primo$$EView_record_in_ProQuest_(subscribers_only)
search
creatorcontrib
0Randell, Paul A
1Jackson, Akil G
2Zhong, Lijie
3Yale, Kitty
4Moyle, Graeme J
titleThe effect of tenofovir disoproxil fumarate on whole-body insulin sensitivity, lipids and adipokines in healthy volunteers.
descriptionBACKGROUNDCertain antiretrovirals are known to affect lipid and glucose homeostasis. The aim of this study was to assess the effect on insulin sensitivity (determined by peripheral glucose uptake using a hyperinsulinaemic euglycaemic clamp) of tenofovir disoproxil fumarate (TDF) administration compared with placebo for 2 weeks in HIV-1-seronegative healthy male volunteers. Changes in lipids, adiponectin, leptin, plasminogen activator inhibitor 1 (PAI-1) and the adhesion molecules E-selectin and P-selectin were also assessed. METHODSThis was a single-centre, randomized, double-blinded, placebo-controlled study that used a two-sequence, two-period cross-over design. A total of 19 HIV-negative males were recruited to the study and randomized 1:1 to receive either 2 weeks of TDF (300 mg once daily) followed by 2 weeks of placebo or placebo initially followed by tenofovir. Clamps were performed at baseline, after 2 weeks and after 4 weeks. RESULTSAll three clamps were completed by 16 participants. During the euglycaemic clamp, there were no significant changes in insulin sensitivity after 2 weeks of TDF administration compared with placebo or baseline. There was a significant reduction in the mean total cholesterol (9.4%) and low-density lipoprotein (LDL; 8.1%) cholesterol following 2 weeks of TDF compared with placebo. Levels of adiponectin, leptin, PAI-1, P-selectin and E-selectin were not significantly altered. CONCLUSIONSTDF use for 2 weeks does not affect insulin sensitivity, as assessed by the hyperinsulinaemic euglycaemic clamp in HIV-negative male volunteers. TDF use resulted in modest, but statistically significant, reductions in total and LDL cholesterol.
subject
0Adenine–Administration & Dosage
1Adipokines–Analogs & Derivatives
2Adult–Pharmacology
3Anti-HIV Agents–Metabolism
4Cholesterol–Administration & Dosage
5Cholesterol, LDL–Pharmacology
6Cross-Over Studies–Metabolism
7Drug Administration Schedule–Drug Effects
8Glucose Clamp Technique–Metabolism
9HIV Seronegativity–Drug Effects
10Humans–Metabolism
11Insulin–Drug Effects
12Insulin Resistance–Administration & Dosage
13Lipid Metabolism–Pharmacology
14Male–Administration & Dosage
15Organophosphonates–Pharmacology
16Reverse Transcriptase Inhibitors–Pharmacology
17Tenofovir–Pharmacology
18Treatment Outcome–Pharmacology
19Young Adult–Pharmacology
20Adipokines
21Anti-HIV Agents
22Cholesterol, LDL
23Insulin
24Organophosphonates
25Reverse Transcriptase Inhibitors
26Cholesterol
27Tenofovir
28Adenine
general
0English
12040-2058
210.3851/IMP1518
3MEDLINE (ProQuest)
4ProQuest Biological Science Collection
5ProQuest Natural Science Collection
6ProQuest SciTech Collection
7Biological Science Database
8Natural Science Collection
9SciTech Premium Collection
10Health Research Premium Collection
11Health Research Premium Collection (Alumni edition)
sourceidproquest
recordidproquest733880007
issn
020402058
12040-2058
rsrctypearticle
creationdate2010
addtitleAntiviral therapy
searchscope
01007527
11007944
210000004
310000038
410000050
510000120
610000159
710000238
810000253
910000260
1010000270
1110000271
1210000302
13proquest
scope
01007527
11007944
210000004
310000038
410000050
510000120
610000159
710000238
810000253
910000260
1010000270
1110000271
1210000302
13proquest
lsr43
01007527false
11007944false
210000004false
310000038false
410000050false
510000120false
610000159false
710000238false
810000253false
910000260false
1010000270false
1110000271false
1210000302false
contributorRandell, Paul A
startdate20100101
enddate20100101
citationpf 227 pt 233 vol 15 issue 2
lsr30VSR-Enriched:[date, issn, pqid]
sort
titleThe effect of tenofovir disoproxil fumarate on whole-body insulin sensitivity, lipids and adipokines in healthy volunteers.
authorRandell, Paul A ; Jackson, Akil G ; Zhong, Lijie ; Yale, Kitty ; Moyle, Graeme J
creationdate20100101
lso0120100101
facets
frbrgroupid5890713665074886941
frbrtype5
newrecords20181218
languageeng
creationdate2010
topic
0Adenine–Administration & Dosage
1Adipokines–Analogs & Derivatives
2Adult–Pharmacology
3Anti-HIV Agents–Metabolism
4Cholesterol–Administration & Dosage
5Cholesterol, LDL–Pharmacology
6Cross-Over Studies–Metabolism
7Drug Administration Schedule–Drug Effects
8Glucose Clamp Technique–Metabolism
9HIV Seronegativity–Drug Effects
10Humans–Metabolism
11Insulin–Drug Effects
12Insulin Resistance–Administration & Dosage
13Lipid Metabolism–Pharmacology
14Male–Administration & Dosage
15Organophosphonates–Pharmacology
16Reverse Transcriptase Inhibitors–Pharmacology
17Tenofovir–Pharmacology
18Treatment Outcome–Pharmacology
19Young Adult–Pharmacology
20Adipokines
21Anti-HIV Agents
22Cholesterol, LDL
23Insulin
24Organophosphonates
25Reverse Transcriptase Inhibitors
26Cholesterol
27Tenofovir
28Adenine
collection
0MEDLINE (ProQuest)
1ProQuest Biological Science Collection
2ProQuest Natural Science Collection
3ProQuest SciTech Collection
4Biological Science Database
5Natural Science Collection
6SciTech Premium Collection
7Health Research Premium Collection
8Health Research Premium Collection (Alumni edition)
prefilterarticles
rsrctypearticles
creatorcontrib
0Randell, Paul A
1Jackson, Akil G
2Zhong, Lijie
3Yale, Kitty
4Moyle, Graeme J
jtitleAntiviral therapy
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0Randell
1Jackson
2Zhong
3Yale
4Moyle
aufirst
0Paul A
1Akil G
2Lijie
3Kitty
4Graeme J
au
0Randell, Paul A
1Jackson, Akil G
2Zhong, Lijie
3Yale, Kitty
4Moyle, Graeme J
addauRandell, Paul A
atitleThe effect of tenofovir disoproxil fumarate on whole-body insulin sensitivity, lipids and adipokines in healthy volunteers.
jtitleAntiviral therapy
date2010
risdate20100101
volume15
issue2
spage227
epage233
pages227-233
eissn2040-2058
formatjournal
genrearticle
ristypeJOUR
abstractBACKGROUNDCertain antiretrovirals are known to affect lipid and glucose homeostasis. The aim of this study was to assess the effect on insulin sensitivity (determined by peripheral glucose uptake using a hyperinsulinaemic euglycaemic clamp) of tenofovir disoproxil fumarate (TDF) administration compared with placebo for 2 weeks in HIV-1-seronegative healthy male volunteers. Changes in lipids, adiponectin, leptin, plasminogen activator inhibitor 1 (PAI-1) and the adhesion molecules E-selectin and P-selectin were also assessed. METHODSThis was a single-centre, randomized, double-blinded, placebo-controlled study that used a two-sequence, two-period cross-over design. A total of 19 HIV-negative males were recruited to the study and randomized 1:1 to receive either 2 weeks of TDF (300 mg once daily) followed by 2 weeks of placebo or placebo initially followed by tenofovir. Clamps were performed at baseline, after 2 weeks and after 4 weeks. RESULTSAll three clamps were completed by 16 participants. During the euglycaemic clamp, there were no significant changes in insulin sensitivity after 2 weeks of TDF administration compared with placebo or baseline. There was a significant reduction in the mean total cholesterol (9.4%) and low-density lipoprotein (LDL; 8.1%) cholesterol following 2 weeks of TDF compared with placebo. Levels of adiponectin, leptin, PAI-1, P-selectin and E-selectin were not significantly altered. CONCLUSIONSTDF use for 2 weeks does not affect insulin sensitivity, as assessed by the hyperinsulinaemic euglycaemic clamp in HIV-negative male volunteers. TDF use resulted in modest, but statistically significant, reductions in total and LDL cholesterol.
doi10.3851/IMP1518
urlhttp://search.proquest.com/docview/733880007/
issn13596535